國立虎尾科技大學 |

Immunotherapy of cancer = an innovative treatment comes of age /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Immunotherapy of cancer/ edited by Yoshiyuki Yamaguchi.
其他題名:	an innovative treatment comes of age /
其他作者:	Yamaguchi, Yoshiyuki.
出版者:	Tokyo :Springer Japan : : 2016.,
面頁冊數:	ix, 358 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Cancer - Immunotherapy. -
電子資源:	http://dx.doi.org/10.1007/978-4-431-55031-0
ISBN:	9784431550310

Immunotherapy of cancer = an innovative treatment comes of age /
Immunotherapy of canceran innovative treatment comes of age /[electronic resource] :edited by Yoshiyuki Yamaguchi. - Tokyo :Springer Japan :2016. - ix, 358 p. :ill., digital ;24 cm.

Part I Overview, History, Classification -- Chapter 1 Overview of Current Cancer Immunotherapy -- Part II BRMs and Crude Agents -- Chapter 2 Bacterial Preparations -- Chapter 3 Polysaccharides -- Chapter 4 BCG -- Part III Cytokines -- Chapter 5 αβ-T Cells -- Chapter 6 NKT Cell-Based Immunotherapy -- Chapter 7 Natural Killer Cells -- Chapter 8 γδ T Cell-Based Cancer Immunotherapy -- Chapter 9 Genetically engineered T cells -- Part IV Vaccine Therapy -- Chapter 10 Peptide Vaccine -- Chapter 11 Personalized Peptide Vaccine -- Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies -- Chapter 13 Protein vaccine -- Chapter 14 Dendritic Cell-Based Vaccine for Cancer -- Part V Immunoadjuvants -- Chapter 15 CpG Motif -- Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy -- Chapter 17 Novel Adjuvants -- Part VI Immunocheckpoints -- Chapter 18 Anti-CTLA-4 Ab -- Chapter 19 Anti-PD-1, PD-L1 Ab -- Chapter 20 Novel Targets of Immune Inhibitory and Stimulatory Co-signals -- Part VII Regulation of Immunosuppression -- Chapter 21 Regulatory T Cells -- Chapter 22 MDSC: Myeloid-Derived Suppressor Cells -- Part VIII Immune-Related Response Criteria and Guidance for Clinical Trials -- Chapter 23 Immune-Related Response Criteria and Guidance for Clinical Trials -- Part IX Personalized Immunotherapy -- Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy.

This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.

ISBN: 9784431550310

Standard No.: 10.1007/978-4-431-55031-0doiSubjects--Topical Terms:

645557
Cancer
--Immunotherapy.

LC Class. No.: RC271.I45

Dewey Class. No.: 616.99406

Immunotherapy of cancer = an innovative treatment comes of age /
LDR:03828nam a2200313 a 4500 001 862718
003 DE-He213
005 20160822105833.0
006 m d
007 cr nn 008maaau
008 170720s2016 ja s 0 eng d
020 $a 9784431550310 $q (electronic bk.)
020 $a 9784431550303 $q (paper)
024 7 $a 10.1007/978-4-431-55031-0 $2 doi
035 $a 978-4-431-55031-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b I33 2016
245 0 0 $a Immunotherapy of cancer $h [electronic resource] : $b an innovative treatment comes of age / $c edited by Yoshiyuki Yamaguchi.
260 $a Tokyo : $c 2016. $b Springer Japan : $b Imprint: Springer,
300 $a ix, 358 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part I Overview, History, Classification -- Chapter 1 Overview of Current Cancer Immunotherapy -- Part II BRMs and Crude Agents -- Chapter 2 Bacterial Preparations -- Chapter 3 Polysaccharides -- Chapter 4 BCG -- Part III Cytokines -- Chapter 5 αβ-T Cells -- Chapter 6 NKT Cell-Based Immunotherapy -- Chapter 7 Natural Killer Cells -- Chapter 8 γδ T Cell-Based Cancer Immunotherapy -- Chapter 9 Genetically engineered T cells -- Part IV Vaccine Therapy -- Chapter 10 Peptide Vaccine -- Chapter 11 Personalized Peptide Vaccine -- Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies -- Chapter 13 Protein vaccine -- Chapter 14 Dendritic Cell-Based Vaccine for Cancer -- Part V Immunoadjuvants -- Chapter 15 CpG Motif -- Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy -- Chapter 17 Novel Adjuvants -- Part VI Immunocheckpoints -- Chapter 18 Anti-CTLA-4 Ab -- Chapter 19 Anti-PD-1, PD-L1 Ab -- Chapter 20 Novel Targets of Immune Inhibitory and Stimulatory Co-signals -- Part VII Regulation of Immunosuppression -- Chapter 21 Regulatory T Cells -- Chapter 22 MDSC: Myeloid-Derived Suppressor Cells -- Part VIII Immune-Related Response Criteria and Guidance for Clinical Trials -- Chapter 23 Immune-Related Response Criteria and Guidance for Clinical Trials -- Part IX Personalized Immunotherapy -- Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy.
520 $a This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.
650 0 $a Cancer $x Immunotherapy. $3 645557
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Oncology. $3 593951
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Immunology. $3 592892
700 1 $a Yamaguchi, Yoshiyuki. $3 1106241
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-4-431-55031-0
950 $a Medicine (Springer-11650)